https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-40th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/aspavelir-pegcetacoplan-approved-in-eu-as-orphan-drug-for-treatment-of-pnh-2021-12-15
https://www.nasdaq.com/press-release/apellis-and-sobi-announce-eu-approval-of-aspavelir-pegcetacoplan-for-treatment-of-pnh
https://www.nasdaq.com/press-release/apellis-and-sobi-report-empavelitm-pegcetacoplan-demonstrated-sustained-normalization
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-4th-annual-evercore-isi-healthconx
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-0
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-2021-11
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2021-11-15
https://www.nasdaq.com/press-release/apellis-reiterates-plans-to-submit-a-new-drug-application-in-the-first-half-of-2022
https://www.nasdaq.com/press-release/apellis-announces-three-oral-presentations-of-the-phase-3-derby-and-oaks-data-in
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-third-quarter-2021-financial-results-2021-11-08
https://www.nasdaq.com/press-release/apellis-to-present-new-data-reinforcing-empavelitm-pegcetacoplan-efficacy-and-safety
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-11-03
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-host-conference-call-on-november-8-2021-to-discuss-third
https://www.nasdaq.com/press-release/aspavelir-pegcetacoplan-receives-positive-chmp-opinion-for-treatment-of-pnh-2021-10
https://www.nasdaq.com/press-release/apellis-and-sobi-receive-positive-chmp-opinion-for-aspavelir-pegcetacoplan-for-the
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-25
https://www.nasdaq.com/press-release/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-2021-cantor-virtual-global-healthcare
https://www.nasdaq.com/press-release/apellis-announces-top-line-results-from-phase-3-derby-and-oaks-studies-in-geographic
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-24
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-23
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-second-quarter-2021-financial-results-2021-08-09
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-22
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-host-conference-call-on-august-9-2021-to-discuss-second
https://www.nasdaq.com/press-release/apellis-announces-closing-of-previously-announced-exchanges-of-approximately-%24201.1
https://www.nasdaq.com/press-release/apellis-announces-agreements-to-exchange-approximately-%24198.6-million-in-principal
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-21
https://www.nasdaq.com/press-release/apellis-and-beam-therapeutics-enter-exclusive-research-collaboration-to-apply-base
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-host-rd-day-on-june-30-2021-2021-06-23
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-06-03
https://www.nasdaq.com/press-release/acuamark-diagnostics-welcomes-dr.-cedric-francois-to-its-board-of-directors-2021-06
https://www.nasdaq.com/press-release/positive-top-line-results-from-the-phase-3-prince-study-of-pegcetacoplan-in-treatment
https://www.nasdaq.com/press-release/apellis-and-sobi-report-positive-top-line-results-from-the-phase-3-prince-study-of
https://www.nasdaq.com/press-release/apellis-announces-u.s.-food-and-drug-administration-fda-approval-of-empavelitm
https://www.nasdaq.com/press-release/apellis-to-present-long-term-pegcetacoplan-data-in-pnh-at-the-european-hematology
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-20
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-first-quarter-2021-financial-results-2021-04-28
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-hold-first-quarter-2021-earnings-conference-call-on-april
https://www.nasdaq.com/press-release/apellis-to-showcase-leadership-in-retina-at-association-for-research-in-vision-and
https://www.nasdaq.com/press-release/apellis-provides-24-month-update-from-phase-1b-study-of-pegcetacoplan-in-patients
https://www.nasdaq.com/press-release/the-nejm-publishes-phase-3-pegasus-study-results-comparing-pegcetacoplan-to
https://www.nasdaq.com/press-release/apellis-and-sobi%3a-the-new-england-journal-of-medicine-publishes-phase-3-pegasus-study
https://www.nasdaq.com/press-release/apellis-announces-two-new-publications-from-the-positive-phase-2-filly-study
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-19
https://www.nasdaq.com/press-release/apellis-provides-update-on-apl-9-for-severe-covid-19-2021-03-04
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-02-22
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-hold-fourth-quarter-and-full-year-2020-earnings-conference
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-18
https://www.nasdaq.com/press-release/apellis-announces-closing-of-previously-announced-exchanges-of-approximately-%24126.1
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-host-investor-event-on-geographic-atrophy-on-january-28
https://www.nasdaq.com/press-release/apellis-announces-agreements-to-exchange-approximately-%24107.5-million-in-principal
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-39th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/sobi-and-apellis-report-positive-top-line-results-at-48-weeks-from-the-phase-3
https://www.nasdaq.com/press-release/apellis-and-sobi-report-positive-top-line-results-at-48-weeks-from-the-phase-3
https://www.nasdaq.com/press-release/apellis-reports-pegcetacoplan-demonstrates-greater-treatment-responses-and-quality-of
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-17
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-2020-evercore-isi-healthconx-conference
https://www.nasdaq.com/press-release/sobi-and-apellis-announce-first-patient-dosed-in-potentially-registrational-als-study
https://www.nasdaq.com/press-release/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study
https://www.nasdaq.com/press-release/apellis-announces-fda-acceptance-and-priority-review-of-the-new-drug-application-for
https://www.nasdaq.com/press-release/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-2020-11-11
https://www.nasdaq.com/press-release/apellis-to-present-new-data-supporting-the-efficacy-and-safety-of-pegcetacoplan-in
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-third-quarter-2020-financial-results-2020-11-02
https://www.nasdaq.com/press-release/apellis-and-sobi-enter-collaboration-for-global-co-development-and-ex-us
https://www.nasdaq.com/press-release/apellis-announces-18-month-data-from-phase-1b-study-of-pegcetacoplan-in-patients-with
https://www.nasdaq.com/press-release/apellis-announces-new-data-demonstrating-correlation-between-complement-activation
https://www.nasdaq.com/press-release/apellis-to-present-positive-results-from-the-phase-2-discovery-study-of-pegcetacoplan
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-16
https://www.nasdaq.com/press-release/apellis-initiates-registrational-programs-of-pegcetacoplan-in-patients-with-c3g-ic
https://www.nasdaq.com/press-release/apellis-announces-new-analysis-demonstrating-targeted-c3-therapy-pegcetacoplan-slows
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-stifels-2020-immunology-and-inflammation
https://www.nasdaq.com/press-release/apellis-announces-late-breaking-presentation-of-targeted-c3-therapy-pegcetacoplan-in
https://www.nasdaq.com/press-release/apellis-announces-submission-of-pegcetacoplan-marketing-applications-to-fda-and-ema
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-15
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-2020-09-02
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-14
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-13
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-second-quarter-2020-financial-results-2020-07-31
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-12
https://www.nasdaq.com/press-release/apellis-completes-enrollment-in-two-phase-3-studies-of-the-targeted-c3-therapy
https://www.nasdaq.com/press-release/apellis-completes-enrollment-in-phase-3-study-of-pegcetacoplan-in-treatment-naive
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-bmo-2020-prescriptions-for-success
https://www.nasdaq.com/press-release/new-pivotal-data-demonstrate-superiority-of-apellis-pegcetacoplan-to-eculizumab-in
https://www.nasdaq.com/press-release/apellis-announces-investor-conference-call-to-discuss-phase-3-pegasus-data-to-be
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-11
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-goldman-sachs-41st-annual-global-healthcare
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-10
https://www.nasdaq.com/press-release/apellis-initiates-phase-1-2-study-of-apl-9-in-patients-with-severe-covid-19-2020-05
https://www.nasdaq.com/press-release/apellis-announces-plans-to-submit-nda-for-pegcetacoplan-in-paroxysmal-nocturnal
https://www.nasdaq.com/press-release/apellis-to-present-pivotal-paroxysmal-nocturnal-hemoglobinuria-pnh-data-at-25th-eha
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-bofa-securities-2020-health-care-conference
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-9
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-private-placement-of-convertible-senior-notes-2020
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-first-quarter-2020-financial-results-2020-04-29
https://www.nasdaq.com/press-release/apellis-reports-analysis-from-phase-1b-geographic-atrophy-study-2020-04-28
https://www.nasdaq.com/press-release/paul-fonteyne-joins-apellis-board-of-directors-2020-04-06
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-40th-annual-cowen-health-care-conference
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-8
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-full
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-2020-01
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2020-01-07
https://www.nasdaq.com/press-release/apellis-reports-positive-top-line-results-from-phase-3-head-to-head-study-of
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-38th-annual-j.p.-morgan-healthcare
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-upcoming-investor-conferences-2019-11-26
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-7
https://www.nasdaq.com/press-release/apellis-presents-first-data-on-apl-2-in-c3-glomerulopathy-at-asn-kidney-week-2019-11
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-6
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-reports-third-quarter-2019-business-update-and-financial
https://www.nasdaq.com/press-release/apellis-to-present-data-on-apl-2-in-complement-3-glomerulopathy-at-asn-kidney-week
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-4
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-to-present-at-the-2019-cantor-global-healthcare-conference
https://www.nasdaq.com/press-release/phase-2-study-published-in-ophthalmology-highlights-efficacy-and-safety-data-of
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-closing-of-offering-of-convertible-senior-notes
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-pricing-of-offering-of-convertible-senior-notes
https://www.nasdaq.com/press-release/apellis-pharmaceuticals-announces-proposed-private-offering-of-%24200-million-of
